Popular search terms:
Search Results Label
33 results found-
Seqirus Begins Shipping 2017-2018 Influenza Vaccines to the U
Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.
https://www.seqirus.us/...pping-2017-2018-influenza-vaccines -
Seqirus Begins Shipping 2018 2019 Influenza Vaccines to the US
Seqirus Begins Shipping 2018-2019 Influenza Vaccines to the U.S. Market
https://www.seqirus.us/...nfluenza-vaccines-to-the-us-market -
New Clinical Data Reinforces the Ability of MF59 Adjuvanted Seasonal
Seqirus Presents New Clinical Data that Reinforce the Ability of MF59® Adjuvanted Seasonal and Pandemic Influenza Vaccines to Increase Immune Response
https://www.seqirus.us/...al-and-pandemic-influenza-vaccines -
US Media Release Template Q3 2013
ASX:CSL ABN: 26 260 735 035 On July 31, 2015 the CSL Group and its Affiliates acquired the influenza vaccines business of Novartis AG in the US. The influenza vaccines business,
https://www.seqirus.us/-/media/seqirus-us/news/franchise-shipment-press-release--71116final-530-pm.pdf -
Seqirus Releases Real-World Data Indicating Significantly Greater
Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.
https://www.seqirus.us/...-based-seasonal-influenza-vaccines -
Seqirus Releases First Shipment for 2019 2020 Season
Seqirus is first to begin shipping its portfolio of seasonal influenza vaccines for the upcoming 2019/20 U.S. influenza season.
https://www.seqirus.us/...irst-shipment-for-2019-2020-season -
Seqirus is first-to-market with shipment of seasonal influenza
Seqirus is first-to-market with shipment of seasonal influenza vaccines to the US for the 2016-2017 season
https://www.seqirus.us/...enza-vaccines-for-2016-2017-season -
Seqirus Announces U.S. $140 Million Manufacturing Expansion to
The expansion will allow Seqirus to increase capacity for formulation, fill and finish manufacturing of cell-based and adjuvanted influenza vaccines for global markets.
https://www.seqirus.us/...40-million-manufacturing-expansion -
Seqirus Applauds the Executive Order to Accelerate Enhanced Protection
Seqirus, a leading innovator in influenza vaccines and pandemic preparedness, applauds the Administration for recognizing the urgency of ensuring Americans are better protected against seasonal and pandemic influenza threats by releasing the Executive Order on Modernizing Influenza Vaccines in the United States to Promote National Security and Public Health.
https://www.seqirus.us/...otection-against-influenza-threats -
Seqirus Presents Data at IDWeek Demonstrating Cell Derived Viruses
Seqirus Presents Data at IDWeek Demonstrating Cell-Derived Viruses Have a Closer Match to Circulating Influenza Viruses Compared to Egg-derived Viruses Used in the Production of Influenza Vaccines
https://www.seqirus.us/...demonstrating-cell-derived-viruses